Same-Day Wrinkle Reduction Potentially Achievable with New Botox Variant

Same-Day Wrinkle Reduction Potentially Achievable with New Botox Variant

In the world of aesthetics, a new player is poised to make a significant impact - TrenibotE, a novel short-acting neurotoxin developed by pharmaceutical giant AbbVie. The company, which also owns Allergan Aesthetics, the manufacturer of Botox, is hopeful that TrenibotE will soon receive approval from the U.S. Food and Drug Administration (FDA) later this year or early 2026.

Dr. Ava Shamban, a board-certified dermatologist and investigator on one of TrenibotE's Phase 3 trials, expects this new neuromodulator to offer a solution for those seeking smoothing results but are concerned about the potential side effects associated with traditional neuromodulators.

One of the key advantages of TrenibotE is its rapid onset of action, taking effect as early as eight hours post-injection, significantly faster than traditional neuromodulators like Botox, which can take several days to show results. This swift action could appeal to patients who require quick results, such as for special events.

However, the short-term effects of TrenibotE (lasting two to three weeks) may be seen as a disadvantage by some neuromodulator veterans who prefer the longer-lasting results of traditional neuromodulators. The fast-acting nature of TrenibotE is not intended for the same patient demographic as those who are concerned about the side effects of traditional neuromodulators.

Over 2,100 patients were treated with TrenibotE during the Phase 3 trials, and adverse events were reported to be similar to placebo for up to three consecutive treatments. However, specific details on the potential side effects of TrenibotE have not been made publicly available as of June 2025.

General side effects of similar neurotoxins include injection site reactions and potential gastrointestinal (GI) side effects, but it is unclear if these apply directly to TrenibotE. For the most accurate and up-to-date safety profile, consultation of AbbVie’s official product literature upon FDA approval and post-market surveillance data would be necessary.

At this time, AbbVie has declined to comment on both the approval timing and pricing of TrenibotE. The company's silence leaves dermatologists uncertain about the cost of this new neuromodulator, adding another layer of anticipation to its impending arrival in the market.

In conclusion, TrenibotE, a new fast-acting neurotoxin by AbbVie, is anticipated to offer a solution for those seeking quick results in neuromodulation. However, specific details on its potential side effects are not yet publicly available. For the most accurate and up-to-date information, consultation of AbbVie’s official product literature upon FDA approval and post-market surveillance data would be necessary. TrenibotE is currently not approved by the FDA.

1. Beyond aesthetics, the potential applications of TrenibotE could include rapid treatment of medical-conditions that require quick therapies-and-treatments.
2. In the realm of health-and-wellness, especially skin-care, TrenibotE's rapid onset of action could make it an attractive option for individuals seeking immediate results.
3. Despite its quick action, the long-term effects of TrenibotE on nutrition, metabolism, and other body systems remain unknown, needing further exploration and research.

Read also: